The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells

Oncology Reports

Volumn 21, Issue 5, 2009, Pages 1289-1295

  Büneker, Chirlei ^a   Mohr, Andrea ^a   Zwacka, Ralf Michael ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Apoptosis; Apoptosis inducing ligand 2; Decoy receptor real time PCR; Tumour necrosis factor related apoptosis inducing ligand; Tumour necrosis factor related apoptosis inducing ligand receptor

Indexed keywords

DEATH RECEPTOR 4; MESSENGER RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 4; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIGNAL TRANSDUCTION; SOLID TUMOR;

APOPTOSIS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 10C; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 67649304670     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000353     Document Type: Article

References (41)

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C and Smith CA: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
3. Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD and Ashkenazi A: Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol 6: 1669-1676, 1996.
4. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
5. LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75, 2003.
6. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113, 1997.
7. Pan G, Ni J, Wei YF, Yu G, Gentz R and Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818, 1997.
8. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-430, 2002.
9. Bratton SB, MacFarlane M, Cain K and Cohen GM: Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res 256: 27-33, 2000.
10. Srivastava RK: Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol Cell Biol Res Commun 4: 67-75, 2000.
11. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997.
12. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G and Klein J: Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61: 82-90, 2008.
13. Griffith TS and Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998.
14. Henson ES, Johnston JB and Gibson SB: The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 49: 27-35, 2008.
15. Humphreys RC and Halpern W: Trail receptors: targets for cancer therapy. Adv Exp Med Biol 615: 127-158, 2008.
16. Ndozangue-Touriguine O, Sebbagh M, Merino D, Micheau O, Bertoglio J and Breard J: A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27: 6012-6022, 2008.
17. Thorburn A, Behbakht K and Ford H: TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 11: 17-24, 2008.
18. Srivastava RK: TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546, 2001.
19. French LE and Tschopp J: Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J Exp Med 190: 891-894, 1999.
20. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E and Dimanche-Boitrel MT: Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 61: 1645-1651, 2001.
21. Mongkolsapaya J, Cowper AE, Xu XN, Morris G, McMichael AJ, Bell JI and Screaton GR: Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 160: 3-6, 1998.
22. Ma YF, Zhang J, Zhao YP, Yang DL and Chen YH: Correlation between sensitivity to TRAIL and expression level of DR5 on surface of tumor cells. Zhonghua Zhong Liu Za Zhi 26: 528-530, 2004.
23. Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jegou B, Patard JJ and Guillaudeux T: Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 66: 987-995, 2006.
24. Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA and Sanlioglu S: Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther 18: 39-50, 2007.
25. Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, Barry F, O'Brien T and Zwacka R: Mesenchymal Stem Cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med (In press).
26. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
27. Braeuer SJ, Buneker C, Mohr A and Zwacka RM: Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 4: 715-728, 2006.
28. Mohr A, Buneker C, Gough RP and Zwacka RM: MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. Oncogene 27: 763-774, 2008.
29. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Jang JJ, Han JY, Lee JY and Yoo NJ: Alterations of the DR5/ TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 59: 5683-5686, 1999.
30. Ozoren N, Fisher MJ, Kim K, Liu CX, Genin A, Shifman Y, Dicker DT, Spinner NB, Lisitsyn NA and El Deiry WS: Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 16: 917-925, 2000.
31. Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C and Krainer M: Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3: 335-343, 2005.
32. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS and Sanlioglu S: Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 26: 158-165, 2008.
33. Hornstein M, Hoffmann MJ, Alexa A, Yamanaka M, Muller M, Jung V, Rahnenfuhrer J and Schulz WA: Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics 5: 123-136, 2008.
34. Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S and Evdokiou A: Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/ TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 89: 206-214, 2003.
35. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, Pelosi E, Vitale A, Chierichini A, Cedrone M, Foa R, Lo CF, Peschle C and Testa U: TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90: 612-624, 2005.
36. Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C, Moller P and Lehnert T: Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8: 3734-3740, 2002.
37. Locklin RM, Federici E, Espina B, Hulley PA, Russell RG and Edwards CM: Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther 6: 3219-3228, 2007.
38. Deligezer U and Dalay N: Expression of the TRAIL receptors in blood mononuclear cells in leukemia. Pathol Oncol Res 13: 290-294, 2007.
39. Lincz LF, Yeh TX and Spencer A: TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15: 1650-1657, 2001.
40. Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dorken B, Ludwig WD and Karawajew L: In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 15: 921-928, 2001.
41. Kruyt FA: TRAIL and cancer therapy. Cancer Lett 263: 14-25, 2008.